Results from the phase II POPLAR study presented at the 2015 ASCO annual meeting showed that atezolizumab improved median OS compared with docetaxel in previously treated patients with PD-L1 strong positive NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.